How has robotic repair changed the landscape of mitral valve surgery?

Amit K. Taggarse, Rakesh M. Suri, Richard C. Daly

Division of Cardiovascular Surgery, Mayo Clinic, Rochester, MN 55905, USA

Correspondence to: Rakesh M. Suri, MD, DPhil. Division of Cardiovascular Surgery, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. Email: rakesh.m.suri@gmail.com.

The introduction of robotic technology has revolutionized the performance of certain cardiac surgical procedures such as mitral valve (MV) repair. The foundation of modern MV repair was laid by Dr. Dwight C. McGoon in 1958. The operation was first performed with robotic assistance by Carpentier in 1998 using rudimentary motion-assisted equipment. Today, four generations later, telemanipulation technology enables surgeons to carry out all known methods of MV repair traditionally performed by conventional sternotomy; utilizing tiny port access incisions to safely and reliably eliminate mitral regurgitation. Extubation in the operating room following robotic MV repair is now routine and its benefits are well-documented, including transfer to the step-down from the intensive care unit several hours after surgery. This, in turn, translates into diminished usage of blood products, decreased need for pain medication, earlier dismissal from hospital, more rapid return to work and improved patient satisfaction. In addition, smaller, more cosmetically appealing scars and comparable short and mid-term outcomes of robotic and open MV repair have made the robotic approach a preferred option for many patients who meet appropriate safety criteria. As these procedures become more commonplace in large structural heart practices, it is important to reflect upon how the robotic approach has changed the landscape of MV surgery. We discuss the evolution and current status of robotic MV repair founded upon the principles of safe and effective open mitral valvuloplasty techniques. We will explore the potential of the robotic platform to improve both early referral and patient acceptance of interventions to eliminate severe degenerative mitral regurgitation.

Keywords: Robotic; mitral valve (MV) repair

Submitted Nov 10, 2014. Accepted for publication Nov 14, 2014.

View this article at: http://dx.doi.org/10.3978/j.issn.2225-319X.2014.12.09

Introduction

The principles of mitral valve (MV) repair were established soon after the development of the cardiopulmonary bypass (CPB) machine, as correction of congenital abnormalities became more routinely performed. In 1958, Dr. Dwight C. McGoon at Mayo Clinic introduced a durable technique to repair MV prolapse via a right thoracotomy approach, by reducing the flail segment using an inverting pleating stitch of 3-0 silk suture (Figure 1). He additionally closed clefts with interrupted sutures and performed commissuroplasty. Dr. McGoon’s strong emphasis on the principle of repairing the leaflet itself as opposed to using annuloplasty alone or employing an immobile prosthesis for leaflet substitution laid the foundation upon which modern repair techniques are based (1). Dr. Hartzell V. Schaff further modified the McGoon plication technique by performing triangular leaflet resection for redundant myxomatous leaflet tissue. Schaff reasoned that an unfolded McGoon plication was triangular in shape and further more, that leaflet debulking during resection enabled more symmetrical leaflet coaptation, delivering an aesthetically appealing result. He and his colleagues from Mayo Clinic subsequently demonstrated excellent long term results of posterior leaflet based repairs using triangular resection, supported with a standard length flexible posterior annuloplasty band (63 mm) anchored...
between left and right fibrous trigones (2,3). Standard length annuloplasty is based upon the principle that dilatation of the mitral annulus in degenerative disease primarily occurs posteriorly, and that reduction to a standard size supports coaptation and protects the leaflet repair without causing stenosis or systolic anterior motion (SAM) of the anterior mitral leaflet. Prolapse of anterior leaflet scallops is effectively addressed with artificial Gore-Tex neochordae, which have been popularized worldwide (4).

Other major contributions to present day repair techniques were made by Carpentier (5), who standardized valve analysis and MV repair using quadrangular resection and sliding leaflet plasty. He also performed the first robotic MV repair in 1998 in France (6) using an early model of the da Vinci Surgical system (Intuitive Surgical Inc., Mountain View, CA). Soon thereafter, Dr. Friedrich Mohr at the Leipzig Heart Center in Germany (7) expanded the scope of robotic cardiac surgery by performing both coronary and mitral procedures before adopting a video-assisted thoracotomy-based approach. In the USA, the first robotic MV repair was carried out by Chitwood in 2000 (8), who performed middle scallop resection and a band annuloplasty. The totally endoscopic approach, popularized by Vanermen and Casselman (9), remains the most frequent video-assisted platform in Europe. Some contend that dispersion of the thoracoscopic procedure will be impeded by the limited dexterity of long-shafted non-wristed instruments in a small space and the often-associated difficulty in visualizing the entire MV field. The robotic platform consequently evolved in order to address these challenges. A multicenter trial led to the Food and Drug Administration approval of the robotic platform for this purpose in 2005 (10,11) and several large centers have subsequently established active robotic MV repair programs. Building upon these trends, we sought to translate the principles of durable open MV repair employed at Mayo Clinic, into the closed chest milieu, utilizing robotic assistance and port-access incisions. In doing so, we developed a program capable of equally addressing all categories of leaflet prolapse, from simple to complex anterior or bileaflet pathology, with equivalent short term outcomes in comparison to propensity matched patients undergoing open operations (12).

What do North American trends show? According to a recent executive summary report of Society of Thoracic Surgeons adult surgery database, 1,041 sites reported 278,571 cardiac procedures in 2013, of which 6,554 were isolated MV replacements (MVR) and 8,814 isolated MV repair. An overall mortality of 5% was reported for MVR.

Figure 1 Technique of mitral valve repair of flail segment of posterior mitral leaflet with ruptured chord, demonstrated by Dr. Dwight C. McGoon in 1958 at Mayo Clinic. Access was by right anterolateral thoracotomy. Technique was by pleating the flail segment by 3-0 silk. LA, left atrium. (A), the placement of sutures to pleat the untethered segment; (B), pleating of segment caused by a ruptured chordae tendinae; (C), completion of valvuloplasty; (D), completion of the valvuloplasty.
with a mean post-procedure length of stay of 10 days. Mortality was 1.1% for MV repair (combined approaches) with a mean length of stay of 7 days. Our own institutional experience at Mayo Clinic parallels these results with an early mortality of 0.2% with a median hospital stay of 3 days for robotic MV repair.

A more recent minor data request from the STS Database in 2014 for the period January 1, 2005 to March 31, 2014 demonstrates that minimally invasive techniques are becoming more frequently utilized amongst centers reporting to the Registry. Of the 62,620 total MV repair procedures performed during this period, 7,025 (11.22%) were carried out using robotic assistance (Figure 2A). Since a specific code for robotic procedures was gradually introduced, an increasingly accurate estimate of the number of robotic procedures performed annually in the USA is now available. Amongst 8,814 MV repair operations, 1,132 (12.84%) were done using robotic assistance (Figure 2B) in 2013; similar to a previously reported trend (13).

On the world stage, MV primary disease pathology can broadly be divided into degenerative disease, which is the predominant subset treated in developed nations, versus rheumatic pathology, which more often attracts surgical attention in underdeveloped nations. In those regions where degenerative MV disease is frequently treated, right chest thoracoscopic-alone and robot-assisted procedures are increasingly utilized.

**The Mayo Clinic experience**

The Mayo Clinic robotic MV repair program began in 2008 and has been previously described (14). All candidates for the procedure undergo preoperative computed tomography (CT) of chest, abdomen and pelvis to assess vascular disease of the aorta and ilio-femoral vessels. Contraindications for a robotic approach using peripheral cannulation at the present time include: (I) coronary arterial disease requiring open revascularization; (II) peripheral vascular disease precluding safe cannulation of the femoral vasculature; and (III) prior sternotomy or right thoracotomy. Patients are not selected or excluded based upon leaflet prolapse anatomy or complexity, due to the fact that the exact same valvuloplasty/annuloplasty maneuvers performed via an open chest approach are rigorously duplicated with robotic assistance. Utilizing a lateral 5-port approach [three in the fourth interspace for the camera, dynamic left atrium (LA) retractor and working port; right arm two spaces below and left arm two spaces above], peripheral CPB is typically established through a 1-1.5 cm incision in the right groin. Bicaval venous drainage is secured via femoral and right internal jugular vein access. The aorta is cross-clamped with a transthoracic clamp at approximately the third interspace near the mid-axillary line, and cardioplegia delivery along with left heart venting is carried out via a tack vent placed temporarily in the ascending aorta. We reviewed our initial robotic MV repair experience over four quartiles following initiation of the program, demonstrating a distinct temporal learning curve (15). We observed that by the fourth quartile, most patients were extubated in the operating room (OR) with no significant increase in total OR time. We did notice, as have others, that extubation in the OR translated into shorter intensive care unit (ICU) length of stay, lower blood product requirement (13) and total hospital stay (13,16).

We further noted a reduction in intra-operative use of
opioids with a near universal pre-anesthetic placement of thoracic para-vertebral block injecting 0.5% bupivacaine with epinephrine (1:200,000) at two or three levels between T2 and T6. Because we have not modified the technical aspects of MV repair procedure itself to accommodate for a minimally invasive approach, we have routinely been able to repair all subsets of degenerative valve regurgitation involving both leaflets with 100% repair rate in over 500 minimally invasive and robotic repairs to date.

**Cost considerations**

We subsequently analyzed and published the economic impact of open versus robotic MV repair at Mayo Clinic during a period where both techniques were subjected to system-wide cost containment measures (17). We observed that during the initial part of our experience, there was a significantly higher cost early following introduction of robotic MV repair compared to the open, both in the OR and in the post-operative period. We quickly demonstrated however, that technical innovations such as robotics, introduced together with systems innovations including surgical process improvement, significantly decreased overall in-hospital resource utilization. For example, by facilitating extubation of patients in the OR, translating into shorter ICU stay and efficient transfer to step-down the evening of surgery, along with efficient coordination of pre-dismissal echocardiogram, our experience has been that patients are routinely prepared for discharge from hospital by the 3rd postoperative day. These trends have resulted in the overall costs of robotic MV repair becoming indistinguishable from those undergoing open operation at our institution.

**Asymptomatic patients**

Robotic and other less invasive means of performing MV repair, when performed with 99% certainty and <0.3% risk, hold specific relevance for asymptomatic patients with severe degenerative mitral regurgitation (MR). With improved understanding of the adverse natural history of patients undergoing delayed operations for severe MR, referral patterns for MV repair have changed over the past decade, from symptomatic patients often in late stages of the disease state with enlarged left ventricle (LV) size and diminished ejection fraction (EF), to young healthy asymptomatic patients found to have significant MR and normal LV function (EF >60%, LV systolic dimension <40 mm) on echocardiographic examination. The latest American College of Cardiology/American Heart Association (ACC/AHA) heart valve guidelines classify patients with chronic primary MR into four categories: Stage A (those with minimal disease), Stage B (those with progressive disease), Stage C (asymptomatic patients with severe disease), and Stage D (severe symptomatic disease). The asymptomatic group is divided into stage C1 for those without LV dysfunction [left ventricular ejection fraction (LVEF) >60% or left ventricular end systolic diameter (LVESD) <40 mm] and stage C2, those with early evidence of a failing LV (LVEF <60% or LVESD >40 mm). There is general acceptance of the need for surgery for stage D and C2 patients (class of recommendation 1, “must do”) (18).

With evidence now mounting regarding the advantages of prompt surgical correction of degenerative MR in asymptomatic patients with regurgitant volume >60 cc/beat, effective regurgitant orifice area >0.4 cm² and preserved LV size/function (stage C1), resulting in significant survival benefit and lowered risk of heart failure, it is now imperative that these patients are fully informed regarding the benefits and risks of early referral for surgery versus watchful waiting (19-21). The newest ACC/AHA guidelines provide a class IIa (reasonable to intervene) recommendation to offer MV repair for this group of patients (when likelihood of repair is >95% and risk <1%) (18) and state that waiting for the patient to become symptomatic exposes the patient to the risks of sudden death, heart failure and poorer survival with sub-optimal outcomes of future interventions (22-25).

How then can the advantages of early intervention for asymptomatic individuals with severe MR and “normal” LV size/function (stage C1) become more widely accepted by both the referring physician and patient? With minimally invasive methods rapidly achieving critical technical goals, including the restoration of MV anatomy and near complete elimination of MR, it is expected that these procedures will provide benefits similar to those evident in the robust outcomes data associated with open repair, such as reverse LV remodeling, improved EF, protection from sudden death and normalization of survival. Additional benefits, including a minimal scar with prompt return to normal daily activities, have been noted by patients and providers, thus leading to the establishment of robot-assisted MV repair as a new standard against which emerging percutaneous technologies must compete at several major heart valve centers of excellence.

**Looking towards the future: the road ahead**

Robotic MV repair has changed the landscape of heart
valve therapy by presenting an option which facilitates early referral and patient acceptance in those with severe MR. Although robotic programs may be challenging to establish given the infrastructure and human resource investment, they can deliver superb safety, efficacy and patient satisfaction. Percutaneous transcatheter techniques will continue to progress and improve; however, early results in degenerative disease subsets are currently sub-optimal, and thus unsuitable for the majority of such patients who are very low risk candidates for minimally invasive or robotic MV repair (risk <0.9%) (26). Emerging minimally invasive and percutaneous technologies will be closely watched by structural heart specialists around the globe and rigorously compared to well-established open surgical techniques that have traditionally delivered high quality, safe and durable outcomes capable of restoring normal life expectancy in otherwise healthy patients with severe degenerative MR (27,28). We also predict that the gap between less invasive surgical and percutaneous techniques will narrow with time. Robotic technology and instrumentation is also still evolving, and further advancements can be expected in terms of smaller and more versatile equipment, better quality optics and perhaps, inclusion of haptic feedback. Next generation robotic systems that facilitate safe learning, improved ergonomics, enhanced portability and systematic cost reduction are desired deliverables from present and future commercial vendors.

At present, only several large robotic MV repair practices exist in the world (11,12,15,16). Outcomes at these select centers are comparable if not better than results of open techniques from multicenter registry experiences, with very high (95-99%) repair rates and very low (<0.5%) mortality. Robotic MV repair has advanced degenerative MV disease therapy, and potentially its greatest value is in facilitating earlier referral and patient acceptance of a safe and effective MR elimination when class IIa indications for intervention are met.

Acknowledgements

We thank the Society of Thoracic Surgery for the providing the minor data request.

Disclosure: The authors declare no conflict of interest.

References


14. Suri RM, Burkhart HM. Optimizing outcomes of robotic mitral valve repair for all prolapse anatomy: the Suri-